This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Teva Dividend Could Be Hurt by Bank of Israel’s Rate Cut

Stocks in this article: TEVA CHKP

TEL AVIV (TheStreet) -- The recent decision from Bank of Israel to cut its basic cash rate to a historic low of 0.25% could also bring down the dividend payment to investors in leading Israeli companies such as Teva Pharmaceutical Industries (TEVA - Get Report)   and Check Point Software Technologies (CHKP - Get Report) .

Why? This decision may depreciate the Israeli currency, the New Israeli Shekel, against the U.S. dollar, which will translate to lower dividend payments.

Read More: 7 Stocks Warren Buffett Is Selling in 2014

The latest rate cut is prompted by Bank of Israel's goal to jump-start the economy, especially considering the current adverse impact of the war between Israel and Hamas.

Moreover, inflation in the past year was only at 0.3%, well below BOI's target inflation. Low inflation also indicates low economic activity in Israel.

This decision was also made the support Israeli exports in an attempt to devalue the NIS against leading currencies, including the U.S. dollar and the euro.

Following this decision, the exchange rate between the U.S. dollar and the NIS rose by 0.8% to 3.57 -- its highest level this year. If BOI were to take additional steps to heat up the economy, as other leading central banks have taken over the years -- the U.S. Federal Reserve's FOMC and Bank of Japan implemented long term bond purchase programs, or quantitative easing, and the European Central Bank reduced its deposit rate to a negative level -- this could depreciate the NIS even further.

Teva closed Wednesday up 0.11%, with shares at $52.28. Check Point's stock closed at $70.34 -- up by 0.92% . 

For Teva investors in the U.S., this could reduce their dividend paycheck. In the past quarter, Teva paid a quarterly dividend of NIS 1.21, which was around 35.3 cents. If the U.S. dollar/NIS exchange rate were to fall  by 10%, this could mean its dividend of NIS 1.21 will be roughly 30.8 cents per share, and its annual yield will decline from 2.6% to 2.3%. 

Read More: ConocoPhillips, Cut by Warren Buffett, Can Be Yours on the Rebound

Moreover, since a big portion of Teva's sales come from the U.S. -- 55% of its net revenue in the second quarter -- a devaluation of the NIS could also raise earnings in NIS. That could increase the taxes the company will have to pay to the Israeli tax authorities.  

Therefore, the recent devaluation of the NIS may not benefit shareholders of Teva and other leading Israeli companies. Investors should pay close attention to the U.S. dollar/NIS exchange rate.  

At the time of publication, the author held no positions in any of the stocks mentioned.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.


TheStreet Ratings team rates TEVA PHARMACEUTICALS as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

"We rate TEVA PHARMACEUTICALS (TEVA) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results."

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs